Tivdak
Drug
Genmab U.S., Inc.
Total Payments
$2.3M
Transactions
4,649
Doctors
2,097
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.1M | 2,687 | 1,468 |
| 2023 | $1.2M | 1,962 | 1,154 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 87 | 58.8% |
| Consulting Fee | $336,358 | 73 | 14.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $323,670 | 71 | 14.2% |
| Food and Beverage | $136,276 | 4,099 | 6.0% |
| Travel and Lodging | $119,325 | 309 | 5.2% |
| Space rental or facility fees (teaching hospital only) | $25,000 | 10 | 1.1% |
Payments by Type
Research
$1.3M
87 transactions
General
$940,629
4,562 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer. | Genmab U.S., Inc. | $1.3M | 0 |
Top Doctors Receiving Payments for Tivdak
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Kansas City, KS | $1.4M | 97 |
| , MD | Gynecologic Oncology | Glendale, AZ | $84,462 | 62 |
| Chirag Shah | Gynecologic Oncology | Seattle, WA | $84,222 | 53 |
| , DO | Gynecologic Oncology | Albany, NY | $71,057 | 32 |
| , M.D | Gynecologic Oncology | Fort Lauderdale, FL | $69,118 | 50 |
| , MD | Gynecologic Oncology | Pittsburgh, PA | $58,504 | 33 |
| , M.D | Obstetrics & Gynecology | Fort Worth, TX | $45,007 | 44 |
| , MD | Obstetrics & Gynecology | Williamsport, PA | $37,721 | 32 |
| , MD | Obstetrics & Gynecology | San Francisco, CA | $35,529 | 14 |
| , CNP | Women's Health | Columbus, OH | $34,715 | 63 |
| , M.D | Gynecologic Oncology | Los Angeles, CA | $30,556 | 18 |
| , FNP-C | Family | Gastonia, NC | $29,721 | 61 |
| , MD | Obstetrics & Gynecology | Phoenix, AZ | $23,876 | 14 |
| , MD | Obstetrics & Gynecology | Detroit, MI | $20,066 | 15 |
| , M.D | Gynecologic Oncology | Chicago, IL | $19,833 | 21 |
| , MD | Obstetrics & Gynecology | Richmond, VA | $19,423 | 7 |
| , MD | Obstetrics & Gynecology | Huntington, WV | $17,077 | 9 |
| , D.O | Obstetrics & Gynecology | Kansas City, MO | $16,290 | 19 |
| , MD | Gynecologic Oncology | Willow Grove, PA | $15,195 | 12 |
| , MD MPH | Medical Oncology | Boston, MA | $10,926 | 9 |
| , MD | Medical Oncology | Philadelphia, PA | $8,733 | 12 |
| Mae Dechristy | Family | Sewell, NJ | $7,881 | 14 |
| , MD | Internal Medicine | Houston, TX | $6,968 | 8 |
| , M.D | Interventional Cardiology | New Haven, CT | $6,158 | 9 |
| Everett Vokes | Hematology & Oncology | Chicago, IL | $6,140 | 7 |
Ad
Manufacturing Companies
- Genmab U.S., Inc. $2.3M
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 2,097
- Transactions 4,649
About Tivdak
Tivdak is a drug associated with $2.3M in payments to 2,097 healthcare providers, recorded across 4,649 transactions in the CMS Open Payments database. The primary manufacturer is Genmab U.S., Inc..
Payment data is available from 2023 to 2024. In 2024, $1.1M was paid across 2,687 transactions to 1,468 doctors.
The most common payment nature for Tivdak is "Unspecified" ($1.3M, 58.8% of total).
Tivdak is associated with 1 research study, including "A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer." ($1.3M).